



Chiang et al. Cardiovascular Diabetology  (2015) 14:3 
DOI 10.1186/s12933-015-0175-6ORIGINAL INVESTIGATION Open AccessHigher blood aldosterone level in metabolic
syndrome is independently related to adiposity
and fasting plasma glucose
Jui-Kun Chiang1,2, Chi-Ling Chen2,3, Feng-Yu Tseng4, Yu-Chiao Chi2, Kuo-Chin Huang5 and Wei-Shiung Yang2,4*Abstract
Background: Hypoadiponectinemia is a well-known state associated with metabolic syndrome (MetS) and insulin
resistance (IR). Recently aldosterone has been highly associated with high blood pressure, and may thus be a
possible biomarker for MetS and IR. In this study, we investigate the association of aldosterone with MetS and IR,
and compare it with that of adiponectin.
Methods: In this cross-sectional study, we recruited 556 women receiving physical examinations at a general
hospital in central Taiwan. At the time of examination, we collected data on various demographic and physical
characteristics and measured blood levels of aldosterone, adiponectin and a variety of metabolic factors. Multiple
linear regression analysis was performed using adiponectin or aldosterone as the dependent variables.
Results: We found an inverse correlation between blood adiponectin and aldosterone (γ = −0.11, P = 0.009).
Adiponectin levels were lower and aldosterone levels higher in women with MetS that those without (8.1 ± 0.4 vs.
11.5 ± 0.2 μg/mL, P < 0.001 and 691 ± 50 vs. 560 ± 11 pmol/L, P = 0.013, respectively), as they were in women with
and without IR (adiponectin 10.4 ± 0.5 vs. 11.3 ± 0.2 μg/mL, P = 0.003 and aldosterone 635 ± 31 vs. 560 ± 11 pmol/L,
P = 0.022). Although aldosterone was significantly related to body fat %, fasting plasma glucose and serum
creatinine levels, the relationship between adiponectin and aldosterone was not obvious after adjustment in the
multivariate analysis.
Conclusion: Although aldosterone was related to metabolic factors, including body fat % and fasting plasma
glucose in our female subjects, the relationship between aldosterone and adiponectin remains unclear.
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Adiponectin has been found at lower blood levels in
patients with metabolic syndrome (MetS) and its related
co-morbidities, including obesity, type 2 diabetes melli-
tus (DM), dyslipidemia and hypertension [1-4]. In fact,
hypoadiponectinemia may be one of the most important
biomarkers for the MetS and obesity-induced insulin
resistance (IR) [5,6]. Recently, activation of the renin-
angiotensin-aldosterone system (RAAS) has been found
to possibly play a role in the pathogenesis of obesity-* Correspondence: wsyang@ntu.edu.tw
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unless otherwise stated.related hypertension [7]. Two clinical trials have reported
that blocking RAAS by either angiotensin converting
enzyme inhibitors (ACEI) or angiotensin 2 receptor 1
blockers (ARB) can reduce the incidence of new-onset
DM and the studies suggested that this reduction may
have been a result of improvement in insulin sensitivity
[8,9]. Treatment with ACEI or ARB has also been found
to increase blood level of adiponectin in patients with
hypertension [10,11].
Both animal and human studies have suggested that
RAAS may play a role in MetS [12,13]. Previous several
studies of people with high blood levels of aldosterone
found a close assocation between primary aldosteronism
and insulin resistance [14,15] as well as between lower
blood adiponectin levels [16] and a higher prevalence of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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serve as a biomarker for MetS and IR [19,20]. Such an
association has in fact been observed in two German
populations [21].
The RAAS might also be a potential mediator of adi-
ponectin activity [22]. Compared to men, women have
been found to have higher blood levels of adiponectin
[23] and aldosterone [24]. Despite these findings, the
relationship between these two hormones in MetS and
IR remain unclear. In an effort to better clarify their re-
lationship, we surveyed 556 women in a routine health
checkup and analyzed their blood levels of aldosterone
in relation to MetS, IR and related co-morbidities, and
compared the results with those for adiponectin.
Methods
Subjects
A total of 556 females who underwent a general health
examination at Buddhist Dalin Tzu Chi Hospital in south-
ern Taiwan between August 2009 and June 2012 were in-
cluded in this study. Although we recruited male subjects,
there were not enough to conduct a statistically powerful
study of that gender number. Furthermore, because an-
drogen has been shown to decrease adiponectin levels
[25], their exclusion from the study may also be justified
from this standpoint. In addition, subjects with current
malignancy, infections, such as tuberculosis, or major
organ failure, such as heart failure, liver cirrhosis and
uremia were also excluded. Written informed consent was
obtained from all subjects. This study was approved by
the Institutional Review Board of the Buddhist Dalin Tzu
Chi Hospital (No. B09801018-1 and B09901018). Demo-
graphic data, including age, gender, education levels, life
style, and brief medical history, were collected. Anthropo-
metric data, including body weight, body height and waist
circumference, were measured. Seventy-seven subjects
met the modified National Cholesterol Education Program
definition of metabolic syndrome for Asians: (1) fast-
ing glucose level > 5.55 mmol/L (100 mg/dL) or known
diabetes with anti-diabetic treatment, (2) blood pres-
sure > 130/85 mmHg or known hypertension with
anti-hypertensive treatment, (3) fasting serum trigly-
ceride level ≥1.70 mmol/L (150 mg/dL), (4) fasting
HDL-C level < 1.30 mmol/L (50 mg/dL), and (5) waist
circumference ≥80 cm. Body fat percentage was measured
using a Body Composition Analyzer (Model TBF-410,
Tanita Corporation, Tokyo, Japan). Sitting blood pressure
was measured by an auto blood pressure machine
(ProCare 100, GE Medical System Information Technolo-
gies, Inc., Piscataway, NJ, USA).
Laboratory tests
The tests of the overnight fasting blood samples, includ-
ing those for lipids, sugar, blood cell counts and otherbiochemical items, were assayed by an auto-analyzer
(Sysmex XE-2100 Blood Cell Analyzer, Kobe, Japan).
The human insulin ELISA kit (BioSource Europe S.A.,
Nivelles, Belgium) was used for the insulin assay. The
homeostasis model of assessment (HOMA) was used to
evaluate insulin resistance [26], which was defined as the
HOMA-IR of the highest quartile (≥1.864 in this study).
The human adiponectin ELISA kit (B-Bridge International,
Inc., Mountain View, CA, USA) was used for adiponectin
assay. Aldosterone was measured using a radioimmuno-
assay kit following the manufacturer’s instructions (Adaltis
Italia S.P.A., Bologna, Italy).
Statistical analysis
The data were presented as means ± S.D. or S.E.M. Stu-
dent’s t-test was used to test the difference of means
between two groups. Pearson correlation analysis was
performed to evaluate the correlation between two vari-
ables. Multiple linear regression analysis was performed
using adiponectin or aldosterone as the dependent
variables and the indicated factors as the independent
variables. In the stepwise variable selection procedure,
both the significance levels for entry and stay in the
data set were set at 0.15. The variables considered in
the selection procedure are listed in Table 1, and the
best candidate final regression model was then identi-
fied based on knowledge derived from the literature.
Goodness-of-fit measures, including the coefficient of
determination R2, as well as statistical tools for regression
diagnostics, such as residual analysis, detection of influen-
tial cases, and checking for multi-collinearity, were applied
to discover model or data problems. A p value < 0.05 was
considered significant. The statistical analysis was perfor-
med using STATA version 11.2 (Stata Corp LP, College
Station, TX, USA) and the R 2.15.1 (Free Software Foun-
dation, Inc., Boston, MA, USA) software.
Results
As can been seen in Table 1, a summary of basic charac-
teristics, we recruited 556 women. One hundred twenty-
nine (23.2%) had a BMI ≥ 25 kg/m2 and seventy-nine
(14.2%) a waist circumference ≥ 80 cm. Sixty-seven
(12.1%) had either a fasting plasma glucose ≥ 5.55 mmol/
L (100 mg/dL) or a previous diagnosis of diabetes.
Twenty-eight (5.0%) were taking anti-diabetics medica-
tions and 89 (16.0%) anti-hypertension medications.
Blood adiponectin levels correlated significantly with age,
body weight, body mass index (BMI), waist circumference
(WC), body fat percentage (%), fasting plasma glucose and
insulin, and insulin resistance index (HOMA-IR), triglycer-
ides (TG), high-density lipoprotein cholesterol (HDL-C),
and uric acids (UA) (Table 1). Plasma adiponectin levels
correlated negatively with aldosterone levels (γ = −0.11,
p = 0.009).
Table 1 Basic characteristics of the 556 women and their correlations with adiponectin and aldosterone
Correlation with Adiponectin Correlation with Aldosterone
Variables Mean ± S.D. Γ P= Γ P=
Age (years) 54.4 ± 9.8 0.09 0.032 −0.06 0.195
Height (cm) 155.4 ± 5.6 −0.01 0.805 −0.04 0.918
Weight (kg) 55.7 ± 7.8 −0.25 <0.001 0.07 0.105
BMI (kg/m2) 23.0 ± 3.1 −0.25 <0.001 0.07 0.081
Waist (cm) 72.8 ± 7.2 −0.27 <0.001 0.04 0.410
Body fat (%) 29.0 ± 5.9 −0.29 <0.001 0.19 <0.001
SBP (mmHg) 123.3 ± 19.7 0.06 0.155 0.02 0.680
DBP (mmHg) 71.0 ± 11.3 0.09 0.839 0.07 0.128
AC glucose (mM) 5.0 ± 1.0 −0.15 <0.001 0.20 <0.001
Fasting insulin (IU/mL) 6.3 ± 5.2 −0.10 0.021 0.09 0.034
HOMA-IR 1.4 ± 1.3 −0.13 0.002 0.15 <0.001
TG (mM) 1.2 ± 0.7 −0.25 <0.001 0.09 0.037
T-Chol (mM) 4.8 ± 0.9 0.04 0.365 0.13 0.003
LDL-C (mM) 3.1 ± 0.8 −0.07 0.115 0.11 0.009
HDL-C (mM) 1.5 ± 0.4 0.41 <0.001 −0.03 0.462
BUN (mM) 4.6 ± 1.5 0.04 0.389 0.12 0.006
CRE (μmol/L) 52.1 ± 14.1 0.05 0.246 0.19 <0.001
UA (μmol/L) 279.6 ± 71.4 −0.13 0.003 0.14 0.001
Adiponectin (μg/mL) 11.0 ± 4.9 - - −0.11 0.009
Aldosterone (pmol/L) 577.0 ± 280.2 −0.11 0.009 - -
Abbreviations: BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, AC glucose Fasting plasma glucose, fasting insulin Fasting serum
insulin, HOMA-IR Insulin resistance index by homeostasis assessment model, mM mmol/L, TG Triglycerides, T-Chol Total cholesterol, LDL-C Low-density lipoprotein
cholesterol, HDL-C High-density lipoprotein cholesterol, BUN Blood urea nitrogen, CRE Creatinine, UA Uric acid. Those p values < 0.05 were in bold form.
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fat %, less that found for adiponectin, while correlation
coefficients of adiponectin with BMI, WC and body fat
% were quite comparable those of aldosterone (Table 1).
In addition, like adiponectin, aldosterone was significantly
correlated with fasting plasma glucose, fasting insulin and
HOMA-IR, with magnitudes of the correlation about the
same (Table 1). Although aldosterone was significantlyTable 2 The adiponectin and aldosterone levels in 556 wome
n Adipo
Presence of criteria Yes/No Yes
Waist≥ 80 cm 79/477 8.9 ± 0
Body fat ≥30% 215/339 9.9 ± 0
IFG + diabetes 67/489 8.6 ± 0
SBP > 130 or DBP > 85 mmHg or hypertension 219/337 11.1 ±
TG≥ 1.7 Mm (150 mg/dL) 88/468 9.0 ± 0
HDL-C <1.3 Mm (50 mg/dL) 179/377 8.9 ± 0
Insulin resistance 139/416 10.4 ±
Metabolism syndrome 77/479 8.1 ± 0
*The abbreviations are the same as those in Table 1.
*The values were expressed as Means ± SEM. *Those p values < 0.05 were in bold f
*Two missing for FAT % and one missing for HOMA-IR.
*IFG: impaired fasting glucose: AC glucose ≥ 5.55 mM.
*Insulin resistance was defined as HOMA-IR > higher quartile (1.864 in our study).correlated with TG, it had a much smaller γ than adipo-
nectin. Nevertheless, it was significantly correlated with
total cholesterol (T-Chol) and low-density lipoprotein
cholesterol (LDL-C), but not HDL-C (Table 1). Finally,
aldosterone concentrations were also correlated with uric
acid, blood urea nitrogen and creatinine (Table 1).
The subjects were categorized into those with meta-
bolic syndrome (MetS) and non-MetS groups (Table 2).n belong to various groups
nectin (μg /mL) Aldosterone (pmol/L)
No P= Yes No P=
.5 11.4 ± 0.2 <0.001 535 ± 28 585 ± 14 0.141
.3 11.8 ± 0.2 <0.001 616 ± 22 555 ± 14 0.016
.5 11.4 ± 0.2 <0.001 671 ± 58 566 ± 11 0.081
0.4 11.0 ± 0.3 0.990 605 ± 22 560 ± 14 0.096
.4 11.4 ± 0.2 <0.001 644 ± 33 566 ± 14 0.035
.3 12.1 ± 0.3 <0.001 602 ± 25 566 ± 14 0.219
0.5 11.3 ± 0.2 0.003 635 ± 31 560 ± 11 0.022
.4 11.5 ± 0.2 <0.001 691 ± 50 560 ± 11 0.013
orm.
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were about around thirty percent lower (mean ± SEM:
8.1 ± 0.4 vs. 11.5 ± 0.2 μg/mL, p < 0.001, Figure 1A).
Those meeting none, 1, 2 and 3 and more of the criteria
for MetS had blood adiponectin levels of 12.1 ± 0.3,
11.5 ± 0.4, 10.2 ± 0.4 and 8.1 ± 0.4 μg/mL, respectively
(mean ± SEM., p for trend = 0.030, Figure 1A), while
they had about 19% higher levels of aldosterone (mean ±
SEM: 691 ± 50 vs. 560 ± 11 pmol/L, p = 0.013 with un-
equal variances, Figure 1B). The subjects meeting none, 1,
2 and 3 and more criteria for MetS had blood aldos-
terone levels of 574 ± 17, 558 ± 17, 530 ± 25 and 694 ±
50 pmol/L, respectively (mean ± SEM., p for trend = 0.410,
Figure 1B).
We also categorized subjects based on the various
components of MetS, including central obesity, fasting
glucose, triglycerides, HDL-C levels, and hypertension
and insulin resistance markers (Table 2). We found a
significant difference in adiponectin and aldosterone
levels in centrally obese subjects only. Compared to
those with impaired fasting glucose and diabetes, those
with normal fasting glucose had significantly higher
adiponectin levels and borderline lower aldosteroneFigure 1 The blood (A) adiponectin levels (Mean ± SEM) and (B) aldos
by the number of the MetS criteria met.concentrations. Those with lower fasting plasma triglyc-
erides had significantly higher adiponectin concentra-
tions, but lower aldosterone concentrations, while those
with higher HDL-C levels only had higher adiponectin
levels, but not lower aldosterone levels. We found no
differences in blood adiponectin and aldosterone con-
centrations between subjects with hypertension (SBP >
130 mmHg, DBP > 85 mmHg, or hypertension) and those
with lower blood pressure. Insulin resistance was defined
in subjects belonging to the highest HOMA-IR quartile.
This group was found to have lower adiponectin levels
but higher aldosterone levels (Table 2).
Based on our linear regression analysis, there was a
negative association between adiponectin and aldoster-
one with borderline statistical significance after adjusting
for several variables (Table 3). As expected, a larger waist
circumference, impaired fasting glucose and diabetes
were negatively related to blood adiponectin (Table 3).
In contrast, age and HDL-C levels were positively associ-
ated with adiponectin levels. Using aldosterone as the
dependent variable, we found body fat %, fasting plasma
glucose and serum creatinine levels to be independently
associated with blood aldosterone levels after adjustmentterone levels (Mean ± SEM) in subjects with or without MetS or
Table 3 Multiple linear regression analyses of the association of adiponectin and aldosterone using the stepwise
variable selection procedure
Adiponectin Aldosterone
Covariate β ± SE P= β ± SE P=
Age (per 5 years) 0.445 ± 0.106 <0.001 −7.542 ± 2.218 0.001
Waist (per 10 cm) −1.418 ± 0.283 <0.001 - -
Body fat (per 5%) - - 14.329 ± 3.702 <0.001
SBP (per 10 mmHg) 0.236 ± 0.103 0.023 - -
IFG + DM (yes vs. no) −1.812 ± 0.597 0.003 - -
AC sugar (mM) - - 0.487 ± 0.124 <0.001
HDL-C (mM) 4.512 ± 0.505 <0.001 - -
CRE (per μmol/L) - - 0.039 ± 0.008 <0.001
Adiponectin (μg/mL) - - −0.019 ± 0.025 0.436
Aldosterone (per 100 pmol/L) −0.124 ± .0.065 0.059 - -
R2 0.239 0.104
The abbreviations are the same as those in Table 1. Those p values < 0.05 were in bold form.
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and aldosterone was not demonstrated in this model.
In order take into account possible confounding by
medications being taken by the subjects, we further
subcategorized our 556 subjects into whether they
were taking anti-diabetic medications (n = 28) and anti-
hypertension medications (89). We included these drugs
as independent variables during the stepwise linear regres-
sion and found that they did not significantly affect our
results. Additionally, we also tried excluding these sub-
jects from our analysis and found our results to remain
unchanged.
Discussion
In this study we observed a rise in blood aldosterone
levels along with a fall in blood adiponectin levels in the
subjects with MetS and IR, though there was no strong
independent association between these two factors. Adi-
ponectin appeared to decrease along with the presence
each MetS criterion met in our subjects, whereas aldos-
terone levels were only significantly higher in those sub-
jects with MetS, i.e., those meeting three or more the
criteria.
Aldosterone and aldosterone vs. body fat
The links we found between adiponectin and greater
waist circumference, impaired fasting glucose and diabetes
were expected, because adiponectin is mainly synthesized
and secreted by adipose tissue [27,28]. Adiponectin has
also been found to enhance glucose utilization [29]. How-
ever, we also found a link between aldosterone and body
fat, which is consistent with findings from two previous
studies [20,30]. One recent study investigating gene ex-
pression of the steroidogenic enzymes in human adi-
pose tissue has suggested that de novo biosynthesis of
aldosterone in adipose tissue is not possible due thelack of key enzymes, such as aldosterone synthase
[31]. However, human adipose tissue has been found
to express angiotensinogen and ACE [32,33]. There-
fore, the link we found between aldosterone and body
fat may be at least in part a result effect of angioten-
sin, though further investigations are needed to fully
define the exact mechanism behind this link between
the two.
Aldosterone and insulin resistance
Blood aldosterone levels showed a significant correlation
with the IR index obtained by HOMA in the current
study, similar to our results found for adiponectin. The
current theories regarding the effects of aldosterone on
glucose metabolism primarily focus on IR induced by in-
flammation, oxidative stress, hypokalemia and disturb-
ance of insulin signaling and hepatic gluconeogenesis
[20,34]. However, after detailed analysis of the adipose
tissues from subjects with primary aldosteronism, Urba-
net et al. concluded that IR in primary aldosteronism
might occur in body compartments other than the adi-
pose tissue [14]. Aldosterone may affect glucose metab-
olism in non-adipose tissues, including the islet β-cell
function [34,35]. Some conditions, like obstructive sleep
apnea-hypopnea syndrome (OSAHS) have been associ-
ated with metabolic syndrome [36]. Barceló et al. found
a link between sleep apnea and aldosterone levels and
reported those levels to be reduced by continuous posi-
tive airway pressure (CPAP) therapy after 12 months of
treatment [37]. Kamide, in a cell culture study, reported
that insulin increased the expression of angiotensinogen
and angiotensin II [38], thus it may be possible that car-
diovascular events in subjects with metabolic syndrome
could be reduced with the use of agents that block
RAAS. Cherney et al. reported that treatment with
empaglifozin, a sodium glucose cotransport-2 (SGLT2)
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subjects with type 1 diabetes and that the treatment in-
duced a modest increase in plasma aldosterone levels [39].
The authors of that study proposed that these results
could be related to the fact that SGLT2 inhibitor can cause
a loss in body weight loss and a decrease in insulin secre-
tion. Remírez et al. found eplerenone, an aldosterone
antagonist, able to decrease hyperlipidemia, insulin resist-
ance, myocardial free fatty acid uptake, and the accumu-
lation of reactive oxygen species in an animal model
[40]. However, the exact mechanism through which al-
dosterone modulates glucose tolerance and mediates
the effects of MetS remains elusive, and thus merits further
investigation.
Negative relationship between adiponectin and
aldosterone
The results of our regression model show a negative rela-
tionship between adiponectin and aldosterone, although
this finding was of borderline significance. Aldosterone
plays important roles in blood pressure regulation, and an
inverse relationship between adiponectin and blood
pressure has been reported previously in a study
which also found that human adipocytes produced
mineralocorticoid-stimulating factors that increased
adrenal aldosterone secretion [41]. Increased aldoster-
one levels might then suppress expression of adipo-
nectin protein through the mineralocorticoid receptor,
as well as the glucocorticoid receptor. We postulate
that increased adiposity or obesity directly decreases
adiponectin synthesis in adipose tissue, and indirectly
increases aldosterone production from the adrenal gland,
probably secondary to increased angiotensin production
from the adipose tissues. The results of the current study
suggest that hypoadiponectinemia and hyperaldosteron-
ism may work together to contribute to the development
of glucose intolerance.
Limitation
This study has some limitations. One limitation is that it
was an association study, and thus the cause-effect rela-
tionships cannot be inferred. Another limitation is that
we used only women as study subjects. The observations
reported in this study might thus not be generalized to
men.
Conclusions
Higher blood aldosterone levels and lower blood adipo-
nectin levels were found in the female subjects with
MetS and IR. Aldosterone levels were independently
related to body fat % and fasting plasma glucose. How-
ever, we found no independent relationship between
aldosterone and adiponectin after adjustment of various
anthropometric and metabolic factors.Abbreviations
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